ASCO Updates Fertility Preservation Guidelines for Cancer Patients Starting Treatment

Cancer treatment saves lives - but it can also permanently compromise the ability to have children. Chemotherapy regimens that include alkylating agents, radiation to the pelvis or total body, and some targeted therapies damage the gonads in ways that may be irreversible. The damage can happen quickly, sometimes within a single treatment cycle, and often cannot be repaired after the fact.

For younger patients - those diagnosed with cancer during their reproductive years - the question of future fertility sits alongside the immediate question of survival. These concerns are not mutually exclusive, but they require active management. Without timely counseling and action, options narrow or disappear entirely once treatment begins.

The American Society of Clinical Oncology published updated recommendations on this topic in 2025, now summarized in JAMA. The core principle is unchanged from earlier guidelines but is stated with renewed emphasis: all patients who will undergo cancer treatments with gonadotoxic potential should be informed about their options for fertility preservation, ideally before the first treatment is administered.

What the Guidelines Address

The updated ASCO recommendations cover fertility preservation across a range of patient populations and treatment types. For patients assigned female at birth, established options include embryo cryopreservation (requiring a partner or donor sperm), oocyte cryopreservation (egg freezing), and ovarian tissue cryopreservation - the last of which has moved from experimental to standard practice in recent updates. Ovarian shielding during radiation is recommended where feasible. Gonadotropin-releasing hormone agonists may reduce ovarian damage during certain chemotherapy regimens, though evidence for their protective efficacy varies by regimen.

For patients assigned male at birth, sperm cryopreservation remains the most established and accessible option. It requires only a few days' delay before treatment and can be accomplished at most reproductive medicine facilities. Testicular tissue banking is available at specialized centers and is particularly relevant for prepubertal patients who cannot yet produce mature sperm.

The guidelines also address concerns about offspring health - whether children conceived after cancer treatment face elevated risks of birth defects or health problems. The evidence on this point, drawn from studies of childhood cancer survivors and their children, is generally reassuring: most studies have not found significantly elevated rates of birth defects or genetic disorders in children conceived after cancer treatment, though the data for specific regimens and outcomes remain incomplete.

The Timing Problem

The recommendation to counsel patients before treatment begins runs directly against the reality of cancer diagnosis and treatment logistics. Patients who learn they have cancer and need to begin treatment urgently are often told that any delay is dangerous. That urgency, while sometimes medically justified, can foreclose fertility preservation options that require even a few weeks for egg retrieval or sperm banking.

The challenge for clinical teams is integrating fertility counseling into the narrow window between diagnosis and treatment start. Random controlled trial data on the impact of fertility counseling programs show that structured referral pathways can significantly increase the proportion of eligible patients who access fertility preservation - but implementation requires dedicated coordination between oncology and reproductive medicine teams that many institutions have not fully established.

The guidelines note that clinicians should raise the topic proactively with all patients rather than waiting for patients to ask. Studies of patient experience after cancer treatment consistently show that many patients wish they had been counseled about fertility preservation and did not receive that counseling - often because their care team assumed they were not interested or did not prioritize the topic amid more acute clinical concerns.

Gonadotoxicity Varies Widely by Treatment

Not all cancer treatments carry equal fertility risk. The guidelines provide guidance on stratifying patients by gonadotoxic potential of their planned regimen. High-risk treatments include alkylating agent regimens such as cyclophosphamide, chlorambucil, and procarbazine; pelvic or total body irradiation; and stem cell transplantation conditioning regimens. Moderate-risk treatments include platinum-based regimens and some combination chemotherapy protocols. Lower-risk treatments include antimetabolites, vinca alkaloids, and some targeted therapies.

Age compounds gonadotoxicity: the same treatment that causes temporary gonadal suppression in a 25-year-old may produce permanent infertility in a 38-year-old with a smaller reserve of primordial follicles. Tailoring counseling to the specific combination of treatment intensity and patient reproductive history is part of what the updated guidelines formalize.

Structural Barriers to Implementation

Despite decades of consensus that fertility counseling is a standard of care in oncology, implementation rates remain inconsistent. Cost is a significant barrier: fertility preservation procedures are expensive, insurance coverage is uneven, and financial assistance programs are limited. Patients from lower socioeconomic backgrounds, racial and ethnic minorities, and those in rural areas with limited access to reproductive medicine specialists are disproportionately less likely to complete fertility preservation even when they receive counseling.

The 2025 ASCO update acknowledges these equity concerns. Improving access requires action beyond clinical guidelines - including advocacy for insurance coverage mandates, expansion of patient assistance programs, and development of telemedicine consultation pathways for patients in underserved areas.